Rasagiline

For the treatment of Parkinson's disease, the standard adult dosage of Rasagiline is as follows:

• Monotherapy (Taking Rasagiline alone): The typical dose is 1 mg taken orally once daily. This dose is used for patients in the early stages of the disease who are not yet taking levodopa.
• Adjunct Therapy (Taking Rasagiline with Levodopa): The starting dose is usually 0.5 mg once daily. If the patient does not achieve a sufficient clinical response, the healthcare provider may increase the dose to 1 mg once daily. When Rasagiline is added to levodopa, your doctor may consider reducing the dose of levodopa to minimize the risk of dyskinesia (involuntary movements).

Rasagiline is NOT approved for use in pediatric patients. The safety and effectiveness of Rasagiline in children and adolescents under the age of 18 have not been established. Parkinson's disease is extremely rare in this population, and the pharmacological effects of MAO-B inhibitors on developing neurological systems are not well understood.

Renal Impairment

For patients with mild, moderate, or severe renal (kidney) impairment, no dosage adjustment of Rasagiline is typically required. Because Rasagiline is primarily metabolized by the liver before excretion, kidney function has a minimal impact on the drug's active levels. However, clinical data in patients with end-stage renal disease is limited.

Hepatic Impairment

Your liver plays a vital role in clearing Rasagiline from your body.

• Mild Hepatic Impairment (Child-Pugh Class A): The dose should be limited to 0.5 mg once daily.
• Moderate to Severe Hepatic Impairment (Child-Pugh Class B or C): Rasagiline is contraindicated (should not be used). Patients with significant liver disease can experience plasma concentrations that are several times higher than normal, greatly increasing the risk of toxicity.

Elderly Patients

No specific dosage adjustment is required for elderly patients (over 65). However, older patients may be more sensitive to side effects such as orthostatic hypotension (a drop in blood pressure when standing up) and hallucinations. Healthcare providers typically monitor elderly patients more closely during dose escalation.

• Administration: Rasagiline should be swallowed whole with a glass of water. It can be taken with or without food.
• Consistency: Try to take your dose at the same time every day to maintain steady levels in your bloodstream.
• Dietary Considerations: While Rasagiline is a selective MAO-B inhibitor, high doses of tyramine (found in aged cheeses, air-dried meats, and fermented products) should still be avoided to prevent a potential (though rare) hypertensive crisis.
• Storage: Store tablets at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place, away from light and moisture.

If you miss a dose of Rasagiline, skip the missed dose and take your next dose at the regular scheduled time. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects and blood pressure spikes. If you miss several doses, contact your healthcare provider for guidance on restarting the medication.

Symptoms of a Rasagiline overdose may resemble those of non-selective MAO inhibitors and can be life-threatening. Potential signs include:

• Severe headache
• Irritability and hyperactivity
• High fever (hyperpyrexia)
• Rapid or irregular heartbeat (tachycardia)
• Severe hypertension (high blood pressure) or hypotension (low blood pressure)
• Respiratory depression or coma

In case of a suspected overdose, seek emergency medical attention immediately or contact a Poison Control Center. There is no specific antidote for Rasagiline; treatment is supportive and focuses on managing blood pressure and body temperature.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without direct medical guidance.

In clinical trials, the side effect profile of Rasagiline differed depending on whether it was used alone or with levodopa. Common side effects include:

• Headache: This is the most frequently reported side effect. It is usually mild to moderate and may diminish as the body adjusts to the medication.
• Dizziness and Vertigo: Patients may feel lightheaded or as if the room is spinning. This is often linked to changes in blood pressure.
• Nausea: A feeling of sickness in the stomach. Taking the medication with a small, non-protein snack may help, though you should consult your doctor first.
• Joint Pain (Arthralgia): Some patients report aching in the joints, particularly when Rasagiline is used as monotherapy.

• Orthostatic Hypotension: A sudden drop in blood pressure when standing up from a sitting or lying position. This can lead to fainting (syncope). It is more common during the first few weeks of treatment.
• Dyskinesia: When taken with levodopa, Rasagiline may increase involuntary muscle movements (twitching, swaying). This happens because the drug increases dopamine levels.
• Hallucinations: Seeing or hearing things that are not there. This is more common in elderly patients or those with existing cognitive impairment.
• Abdominal Pain and Constipation: General digestive discomfort.
• Weight Loss: A decrease in body weight has been noted in some adjunct therapy trials.
• Dry Mouth (Xerostomia): Reduced saliva production.

• Skin Cancer (Melanoma): Early clinical trials suggested a potential increase in melanoma risk. While subsequent studies have not definitively proven a causal link, patients are advised to undergo regular skin examinations by a dermatologist.
• Impulse Control Disorders: Patients may experience intense urges to gamble, increased sexual urges, or compulsive spending/eating. These behaviors are often unrecognized by the patient and must be monitored by caregivers.
• Severe Allergic Reactions: Symptoms include rash, itching, or swelling of the face, tongue, and throat.

> Warning: Stop taking Rasagiline and call your doctor immediately if you experience any of these serious symptoms.

• Hypertensive Crisis: Characterized by a sudden, severe headache, nausea, vomiting, stiff neck, rapid heart rate, and sensitivity to light. This can occur if Rasagiline is taken with high-tyramine foods or certain interacting drugs.
• Serotonin Syndrome: A potentially fatal condition if Rasagiline is combined with antidepressants. Symptoms include agitation, hallucinations, rapid heartbeat, fever, muscle stiffness, and loss of coordination.
• Extreme Drowsiness or Falling Asleep during Daily Activities: Some patients have reported falling asleep suddenly while driving or talking, which can lead to accidents.
• Severe Confusion or Psychosis: New or worsening mental status changes.

With prolonged use, the most significant concerns involve the management of motor complications. While Rasagiline helps with 'off' time, the long-term increase in dopamine can lead to persistent dyskinesia that may require adjustments to other Parkinson's medications. Additionally, the risk of impulse control disorders may persist or emerge at any point during long-term therapy. Regular monitoring of blood pressure and mental health is necessary for as long as the patient remains on the drug.

No FDA black box warnings currently exist for Rasagiline. However, it carries significant 'Warnings and Precautions' regarding hypertensive crisis and serotonin syndrome, which are treated with the same level of clinical gravity as black box warnings in practice.

Report any unusual symptoms to your healthcare provider. Your doctor can help determine if a side effect is related to Rasagiline or to the underlying progression of Parkinson's disease.

Rasagiline is a powerful neurological medication that requires careful monitoring. Patients must be aware that while it is highly selective for MAO-B, this selectivity is dose-dependent. Taking more than the prescribed dose can cause it to act like a non-selective MAO inhibitor, significantly increasing the risk of dangerous drug and food interactions.

There are no FDA black box warnings for Rasagiline as of 2026. However, the FDA requires prominent warnings regarding the risk of Hypertensive Crisis and Serotonin Syndrome in the prescribing information.

Hypertensive Crisis (The "Cheese Effect")

Although Rasagiline is selective, it can still cause a rapid, life-threatening rise in blood pressure if taken with foods containing high amounts of tyramine (e.g., aged cheeses, cured meats, fava beans, draft beer). Patients should be educated on a low-tyramine diet. If you experience a sudden, 'thunderclap' headache, seek emergency care immediately.

Serotonin Syndrome Risk

Combining Rasagiline with other drugs that increase serotonin (SSRIs, SNRIs, tricyclic antidepressants, certain pain medications) can lead to Serotonin Syndrome. This is a medical emergency. Do not start any new medication, including over-the-counter cold medicines or supplements, without checking with your pharmacist.

Falling Asleep During Daily Activities

Patients treated with Rasagiline have reported falling asleep without prior warning while engaged in activities of daily living, including the operation of motor vehicles. This can occur at any time during treatment. If you experience increased daytime sleepiness, you must avoid driving and notify your doctor.

Hypotension and Syncope

Rasagiline can cause orthostatic hypotension (low blood pressure upon standing). This is especially risky in the first month of treatment or when the dose is increased. Patients should rise slowly from a sitting or lying position to prevent falls and fractures.

• Blood Pressure: Regular monitoring is essential, especially when starting the drug or changing the dose.
• Skin Checks: Due to the potential risk of melanoma, patients should have their skin checked by a qualified professional (dermatologist) at least once a year.
• Mental Health Screening: Healthcare providers should screen for hallucinations, psychosis, and impulse control disorders (e.g., compulsive gambling or shopping) at every visit.

Rasagiline may cause sudden sleep onset, dizziness, or hallucinations. You should not drive or operate heavy machinery until you know how the medication affects you. If you feel sleepy during the day, do not drive.

Alcohol should be avoided or strictly limited. Alcohol can increase the sedative effects of Rasagiline and may also contribute to unpredictable blood pressure changes. Some alcoholic beverages (like tap beers or certain red wines) also contain tyramine, which increases the risk of a hypertensive crisis.

Do not stop taking Rasagiline abruptly. While it does not have a traditional 'withdrawal' syndrome like benzodiazepines, stopping it suddenly can lead to a rapid return of Parkinson's symptoms or, in rare cases, a condition resembling Neuroleptic Malignant Syndrome (characterized by high fever, muscle rigidity, and autonomic instability). If the drug must be stopped, your doctor will provide a tapering schedule.

> Important: Discuss all your medical conditions, especially liver disease and any history of mental illness, with your healthcare provider before starting Rasagiline.

The following medications must NEVER be used with Rasagiline due to the risk of life-threatening reactions:

• Other MAOIs: Using Rasagiline with other monoamine oxidase inhibitors (e.g., Phenelzine, Selegiline, Tranylcypromine) can cause severe hypertensive crisis. A 14-day washout period is required between stopping one and starting the other.
• Meperidine (Demerol): Combination can lead to fatal reactions involving severe respiratory depression, coma, and hyperpyrexia (extremely high fever).
• Tramadol, Methadone, and Propoxyphene: These combinations carry a high risk of Serotonin Syndrome.
• St. John’s Wort: This herbal supplement significantly increases serotonin levels and can trigger Serotonin Syndrome.
• Cyclobenzaprine: A muscle relaxant that is structurally similar to tricyclic antidepressants and can cause serious adverse reactions.
• Dextromethorphan: Found in many over-the-counter cough medicines; combination can cause 'bizarre' behavior and Serotonin Syndrome.

• Antidepressants (SSRIs/SNRIs): Drugs like Fluoxetine, Sertraline, and Venlafaxine increase the risk of Serotonin Syndrome. If used together, the lowest effective dose should be used, and the patient must be monitored for agitation and tremors.
• Ciprofloxacin and other CYP1A2 Inhibitors: These drugs can block the metabolism of Rasagiline, doubling its concentration in the blood. The dose of Rasagiline should be limited to 0.5 mg if taken with these inhibitors.
• Sympathomimetics: Found in nasal decongestants (e.g., Pseudoephedrine). These can cause severe high blood pressure when combined with MAO-B inhibitors.

• Levodopa: While often used together, Rasagiline increases the effects of levodopa, which can worsen side effects like dyskinesia or hallucinations.
• Oral Contraceptives: May slightly increase the plasma levels of Rasagiline, though usually not enough to require a dose change.

• Tyramine-Rich Foods: Although Rasagiline is selective for MAO-B, patients should avoid large amounts (more than 150 mg) of tyramine. Examples include:
• Aged cheeses (Cheddar, Swiss, Blue, Camembert)
• Cured or processed meats (Salami, Pepperoni)
• Pickled or fermented foods (Sauerkraut, Tofu, Soy Sauce)
• Overripe fruits (Bananas, Figs)
• High-Fat Meals: Can delay the absorption of Rasagiline, though this is usually not clinically significant for most patients.

• Ginseng and Ephedra: May increase blood pressure and heart rate, compounding the cardiovascular risks of Rasagiline.
• 5-HTP and L-Tryptophan: These increase serotonin production and should be avoided to prevent Serotonin Syndrome.

Rasagiline is not known to significantly interfere with most common laboratory tests (such as basic metabolic panels or complete blood counts). However, always inform your laboratory technician and doctor that you are taking an MAO-B inhibitor, as it may theoretically affect certain tests for catecholamines (hormones made by the adrenal glands).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can have dangerous interactions with Rasagiline.

Rasagiline must NEVER be used in the following circumstances:

• Moderate to Severe Hepatic Impairment: Patients with Child-Pugh Class B or C liver disease cannot process the drug effectively. This leads to dangerously high levels of Rasagiline in the blood, which can cause severe toxicity and loss of MAO-B selectivity.
• Pheochromocytoma: A rare tumor of the adrenal gland tissue. Because MAO inhibitors affect the breakdown of catecholamines (like adrenaline), taking Rasagiline with this condition could trigger a catastrophic hypertensive crisis.
• Concurrent use of Meperidine or other MAOIs: As detailed in the interactions section, these combinations are potentially fatal due to the risk of Serotonin Syndrome or hypertensive emergency.
• Hypersensitivity: If you have had a documented severe allergic reaction to Rasagiline Mesylate or any of the inactive ingredients in the tablet, you must not take this medication.

These are conditions where the doctor will carefully weigh the risks versus the benefits:

• Mild Hepatic Impairment: Requires a reduced dose (0.5 mg) and frequent monitoring.
• History of Psychosis: Because Rasagiline increases dopamine, it can worsen symptoms of schizophrenia or other psychotic disorders.
• Elective Surgery: It is often recommended to discontinue Rasagiline at least 14 days before elective surgery that requires general anesthesia to avoid unpredictable interactions with anesthetic agents (especially meperidine-related compounds).
• Existing Skin Lesions: Patients with a history of or active suspicious moles should be cleared by a dermatologist before starting therapy due to the melanoma concerns.

There is no established cross-sensitivity between Rasagiline and other classes of Parkinson's medications (like dopamine agonists or COMT inhibitors). However, patients who have had severe reactions to Selegiline (another MAO-B inhibitor) should be monitored closely, as they may share similar sensitivities to the chemical structure of propargylamines.

> Important: Your healthcare provider will evaluate your complete medical history, including liver function and current medications, before prescribing Rasagiline.

FDA Pregnancy Category

Rasagiline was formerly classified as Category C. There are no adequate and well-controlled studies of Rasagiline in pregnant women. Animal studies (rats and rabbits) have shown some evidence of increased fetal death and decreased fetal body weight at doses much higher than those used in humans.

Clinical Considerations

Rasagiline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you become pregnant while taking Rasagiline, notify your neurologist immediately. It is not currently recommended for use in women of childbearing potential who are not using effective contraception.

It is not known whether Rasagiline is excreted in human milk. However, because many drugs are excreted in human milk and because animal studies have shown that Rasagiline can inhibit prolactin secretion (the hormone that stimulates milk production), caution is advised. The risk to the nursing infant versus the benefit of the drug to the mother must be carefully considered. Most clinicians recommend using alternative treatments or formula feeding while on Rasagiline.

Rasagiline is not approved for use in children. The safety profile has not been tested in patients under 18. Because Parkinson's disease is a condition of the aging brain, there is no clinical indication for its use in pediatric populations.

In clinical trials, approximately 60% of patients were 65 years or older. While no overall differences in effectiveness were observed between these patients and younger patients, the elderly are at a higher risk for:

• Hallucinations and Confusion: The dopaminergic effects are more likely to cause psychiatric symptoms in the aging brain.
• Falls: Due to orthostatic hypotension (blood pressure drops).
• Drug Interactions: Elderly patients are often on multiple medications (polypharmacy), increasing the risk of a drug-drug interaction.

No dose adjustment is necessary for patients with kidney disease. Rasagiline's clearance is not significantly affected by renal function. However, for patients on dialysis, the drug has not been extensively studied, and caution is warranted.

This is the most critical special population for Rasagiline. The liver is the primary site of metabolism.

• Mild Impairment: Maximum dose of 0.5 mg/day.
• Moderate/Severe Impairment: Use is strictly prohibited. Plasma levels can increase by up to 7-fold in these patients, making the drug highly dangerous.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have a history of liver disease.

Rasagiline is an irreversible, selective inhibitor of monoamine oxidase type B (MAO-B). MAO-B is an enzyme located in the mitochondrial outer membrane of cells, particularly within the striatum of the brain. Its primary role is the oxidative deamination (breakdown) of dopamine.

At the molecular level, Rasagiline contains a propargylamine moiety that binds covalently to the N-5 atom of the flavin adenine dinucleotide (FAD) cofactor within the MAO-B enzyme. This creates a stable, inactive complex. By 'locking' the enzyme, Rasagiline prevents it from breaking down dopamine. This results in increased extracellular levels of dopamine in the synaptic cleft, enhancing dopaminergic transmission and alleviating the motor deficits associated with Parkinson's disease.

Rasagiline's pharmacodynamic effect is characterized by a rapid onset of enzyme inhibition. Studies of platelet MAO-B activity (used as a surrogate for brain activity) show that a single 1 mg dose inhibits more than 80% of the enzyme within hours. With daily dosing, inhibition exceeds 95%. Because the bond is irreversible, the effect lasts until new enzyme molecules are synthesized by the body, which typically takes 1 to 2 weeks after the last dose. This explains why drug interactions can still occur long after the medication is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | ~36% (Significant first-pass metabolism) |

| Protein Binding | 88% - 94% (Primarily to Albumin) |

| Half-life | 1.3 - 3.0 Hours (Plasma); Biological effect is 1-2 weeks |

| Tmax | ~1 Hour |

| Metabolism | Hepatic via CYP1A2 |

| Excretion | Renal 62%, Fecal 7% |

• Molecular Formula: C12H13N (as Rasagiline base); C13H17NO3S (as Mesylate salt)
• Molecular Weight: 171.24 g/mol (Base); 267.34 g/mol (Mesylate)
• Solubility: Freely soluble in water and ethanol; sparingly soluble in isopropyl alcohol.
• Structure: It is an R-enantiomer of N-propargyl-1-aminoindan. The R-isomer is significantly more potent (up to 1000 times) than the S-isomer in inhibiting MAO-B.

Rasagiline is classified as a Selective Monoamine Oxidase Type B Inhibitor. It belongs to the propargylamine family. Related medications include Selegiline (Eldepryl, Zelapar) and Safinamide (Xadago). Unlike Selegiline, Rasagiline is not metabolized into L-amphetamine or L-methamphetamine, which is a key clinical distinction that often results in fewer cardiovascular and sleep-related side effects.